# US 2014/0154323 A1 · Method for treating bronchial diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0154323 A1
- Document ID: US20140154323A1
- Status: Published application
- Kind: A1
- Application number: 14/174,624
- Filed: 2014-02-06
- Published: 2014-06-05
- Earliest claimed: 2002-02-22
- Assignees: Microdose Therapeutx, Inc.
- Applicants: Microdose Therapeutx, Inc.
- Inventors: Andrew Abrams
- Web page: https://patentgrep.com/patent/US20140154323A1

## CPC

- A61K 31/341: not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
- A61K 9/0075: {for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles}
- A61K 9/14: Particulate form, e.g. powders, {Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles (microspheres A61K9/16; microcapsules A61K9/50; nanocapsules, nanoparticles of the matrix type A61K9/51)}
- A61K 31/192: having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)}
- A61K 31/34: having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K 31/40: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Administration of a loop diuretic in nebulized dry powder form directly to a patient's lungs for treating bronchial disease.

## Claims

### Claim at position 1

1-9. (canceled)

### Claim 10 (depends on 15)

The method of treatment according to claim 15, wherein the patient suffers from emphysema.

### Claim 11 (depends on 15)

The method of treatment according to claim 15, wherein the patient suffers from cystic fibrosis.

### Claim 12 (depends on 15)

The method of treatment according to claim 15, wherein the patient suffers from chronic bronchitis.

### Claim 13

(canceled)

### Claim 14 (depends on 15)

The method of treatment according to claim 15, wherein the patient suffers from dyspnea.

### Claim 15

A method for relieving a symptom of pulmonary disease in a patient suffering therefrom, wherein the pulmonary disease is selected from the group consisting of emphysema, cystic fibrosis, chronic bronchitis, and dyspnea, comprising delivering directly to the patient's lungs a systemically effective amount of a non-salt formulation of furosemide and ethacrynic acid in dry powder form, wherein said systematically effective amount of a non-salt formulation is delivered as a fine powder having a particle size of 0.5-10 microns.

### Claim 16 (depends on 15)

The method accordingly to claim 15, wherein said systematically effective amount of a non-salt formulation is delivered in unit dose amounts of between about 1 and 100 milligrams.

### Claim 17 (depends on 16)

The method according to claim 16, wherein said systematically effective amount of a non-salt formulation is delivered in unit dose amounts of between about 5 and 10 milligrams.

### Claim 18 (depends on 15)

The method according to claim 15, wherein said systematically effective amount of a non-salt formulation is delivered in discrete doses as needed.

### Claim 19 (depends on 18)

The method according to claim 18, wherein said systematically effective amount of a non-salt formulation is delivered in discrete doses 1-4 times per day.

### Claim 20 (depends on 15)

The method according to claim 15, wherein said systematically effective amount of a non-salt formulation is delivered in dry powder form having a powder size of 1-6 microns.
